A forum for researchers, students and applicants in the field of cyclodextrin technology
CBT-006 is a molecule developed by Cloudbreak Therapeutics that can sequester cholesterol. CBT-006 is a unique topical formulation following 505b(2)
In this work it is reported a one-pot preparation of dual-redox sensitive, stabilized supramolecular nanocontainers for potential programmable drug release
The 2,6-di-O-methyl-β-cyclodextrin (dMβCD) is an amphiphilic annular compound consisting of seven dimethylglucose molecules. This compound is well known as a
The incorporation of cyclodextrin moieties into larger structures produces five types of new materials: crosslinked networks, functionalized chains, amphiphilic cyclodextrins,
As the International Cyclodextrin Symposium (Giardini Naxos, Sicily) has been postponed to 2022 an abridged virtual meeting was organized by
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
Polymers are very important constituents for therapeutic applications as well as the largest and versatile class of biomaterials [1,2]. Synthetic
The incorporation of gold nanoparticles (Au NPs) on graphene (G) is as valuable strategy to produce plasmonic effects that lead
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
A recently published patent application (US20210113666 – Systems, Methods and Products for Minimizing Tissue Reactions and Tissue Injury at an
